1 / 12

The Use of EPO-Stimulating Agents in Heart Failure

The Use of EPO-Stimulating Agents in Heart Failure. Nora Sharaya, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health Network This speaker has no actual or potential conflicts of interest to disclose in relation to this presentation.

mimi
Download Presentation

The Use of EPO-Stimulating Agents in Heart Failure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Use of EPO-Stimulating Agents in Heart Failure Nora Sharaya, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health Network This speaker has no actual or potential conflicts of interest to disclose in relation to this presentation

  2. The Link Between Anemia and Heart Failure ISRN Hematol 2012; 2012: 246915

  3. The Link Between Anemia and Heart Failure • HF with preserved EF • Anemia • HF with unpreserved EF ISRN Hematol 2012; 2012: 246915

  4. Mortality • A meta-analysis published in 2008 examined 153,180 patients with chronic heart failure • Of those patients, 37.2% were anemic • After a minimum of six months follow up, 46.8% of patients with anemia died compared to 29.5% of the patients without anemia • Based on these results, in patients without an identifiable cause for their anemia, using erythropoietin-stimulating agents has been considered J Am CollCardiol. 2008;52:818–2.

  5. Complications J Am CollCardiol 2008;52:818–2

  6. ACCF/AHA Guidelines Circulation. 2013; 128: e240-e327.

  7. Concerns with EPO Stimulating Agents US Boxed Warning: “Erythropoiesis-stimulating agents (ESAs) increased the risk of serious cardiovascular events, thromboembolic events, stroke, and mortality in clinical studies when administered to target hemoglobin levels >11 g/dL.” Darbepoetin (Package Insert)

  8. van Veldhuisen DJ, et al. Eur Heart J. 2007;28:2208–16.

  9. Ghali JK, et al. Circulation. 2008;117:526–35.

  10. Swedberg K, et al. N Engl J Med. 2013;368:1210–19.

  11. Conclusions • Poor Prognostic Sign • Treatment Target

  12. The Use of EPO-Stimulating Agents in Heart Failure Nora Sharaya, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health Network Email: nsharaya2@ecommunity.com

More Related